Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche expects action on Avastin’s European application before the end of the year. Majority share in Genentech stock remains a strategic asset for Roche, CFO says.